BridgeBio Pharma BBIO Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's operating lease right-of-use assets in other assets?
- BridgeBio Pharma (BBIO) reported operating lease right-of-use assets in other assets of $17.23M in Q1 2026.
- How has BridgeBio Pharma's operating lease right-of-use assets in other assets changed year-over-year?
- BridgeBio Pharma's operating lease right-of-use assets in other assets increased by 140.4% year-over-year, from $7.17M to $17.23M.
- What is the long-term trend for BridgeBio Pharma's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), BridgeBio Pharma's operating lease right-of-use assets in other assets has grown at a -13.2% compound annual growth rate (CAGR), from $16.51M to $8.15M.